#ACR 2024 BEST Abstracts from Day 1 Save

The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC.  Here are some of the best abstracts from Saturday Nov. 16th. You can also spot these on Twitter by looking for the (#ACRbest) hashtag. 

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW pic.twitter.com/MjzE14SeGi

— Richard Conway (@RichardPAConway) November 16, 2024

#ACR24 Year in Review:
💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨)
💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?)
💡 High risk of CV events within 30 days of gout… pic.twitter.com/oRNri66Il9

— Adela Castro (@AdelaCastro222) November 16, 2024

LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit

Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit#ACR24 @RheumNow Abstr#0290 #ACRBest pic.twitter.com/kao4vqpPTQ

— Mike Putman (@EBRheum) November 16, 2024

McDermott @jeffsparks et al. SAIL-RA prospective study. 172 early RA patients. RA lund disease in 16%, RA-ILD in 11%. Disease activity strongest predictor RA lung disease, HR 4.89, and RA-ILD, HR 6.17. @RheumNow #ACR24 Abstr#0802 #ACRbest https://t.co/ia0koG64mL pic.twitter.com/U1KdgcUfOy

— Richard Conway (@RichardPAConway) November 16, 2024

Results from SELECT-GCA

➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper
➡️No new safety signals

Is UPA the new kid on the block in #GCA?

Ab0770 #ACRBest #ACR24 @RheumNow pic.twitter.com/pHzozYiid5

— Mrinalini Dey (@DrMiniDey) November 16, 2024

SELECT-GCA: Upa in GCA
Merkel
Upa 15 mg v 7.5 v PBO w slower GC taper
70% new onset, 30% relapse. Few prev on IL6
Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019)
34% relapse in UPA vs 60% PBO
Less steroids, longer time to flare@RheumNow #ACR24 #ACRBest pic.twitter.com/1OV2889Ny0

— Eric Dein (@ericdeinmd) November 16, 2024

Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age!#ACR24 @RheumNow ABST#0516 pic.twitter.com/054RWGh3a7

— Jiha Lee (@JihaRheum) November 16, 2024

A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including:
- Higher BMI 
- Increased comorbidities 
- Presence of EAMs
- HLA-B27 positivity 
is linked to higher odds of being D2T, highlighting potential genetic…

— Antoni Chan MD (Prof) (@synovialjoints) November 16, 2024